natgillin/translations-raw huggingface dataset:
Hence, the CHMP recommended that the change to the marketing authorisation be refused. 
CHMP je zato priporočil zavrnitev spremembe dovoljenja za promet.
Lyrica was expected to be used in patients with moderate to severe pain. 
Zdravilo Lyrica naj bi se uporabljala pri bolnikih z zmerno do hudo bolečino.
Lyrica was also expected to be used to treat adults with fibromyalgia, a disease causing long-lasting, widespread pain and painful responses to touch. 
Zdravilo Lyrica naj bi se uporabljalo tudi za zdravljenje odraslih bolnikov s fibromialgijo, boleznijo, ki povzroča dolgotrajne razširjene bolečine in bolečine ob dotiku.
At that point in time, the CHMP was of the opinion that the benefits of Lyrica in the treatment of fibromyalgia did not outweigh its risks. 
Takrat je CHMP menil, da koristi zdravila Lyrica pri zdravljenju fibromialgije ne odtehtajo z njim povezanih tveganj.
What was Lyrica expected to be used for? 
Za kaj naj bi se zdravilo Lyrica uporabljalo?
The CHMP was concerned that the benefits of Lyrica in fibromyalgia had not been shown in either the short or the long term. 
CHMP je menil, da koristi zdravila Lyrica pri zdravljenju fibromialgije niso bila dokazane niti kratkoročno niti dolgoročno.
How is Lyrica expected to work? 
Kako naj bi zdravilo Lyrica delovalo?
Make the next injection as soon as you remember. 
Naslednji odmerek si injicirajte takoj, ko se spomnite.
Treatment with Binocrit is divided into two stages - correction and maintenance phase. 
Zdravljenje z zdravilom Binocrit poteka v dveh fazah - korekcijska in vzdrževalna faza.
Binocrit should not be used and discarded - if the liquid is coloured or you can see particles floating in it, - if the seal is broken, - if you know, or think that it may have been accidentally frozen, or - if there has been a refrigerator failure. 
Zdravila Binocrit se ne sme uporabiti in ga je treba zavreči: - če je tekočina obarvana ali v njej vidite plavati delce, - če je tesnilo poškodovano, - če veste ali mislite, da je bila raztopina pomotoma zamrznjena ali - če hladilnik ni pravilno deloval.
Your doctor will monitor your blood pressure regularly while you are using Binocrit. 
Zdravnik bo redno nadziral vaš krvni tlak, medtem ko uporabljate zdravilo Binocrit.
Binocrit has no or negligible influence on the ability to drive and use machines. 
Zdravilo Binocrit nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
• For adults and children Binocrit is given as an injection either into a vein (intravenously) or a tube that goes into a vein. 
• Odraslim in otrokom se daje zdravilo Binocrit v obliki injekcije bodisi v veno (intravensko) ali s cevko, ki gre v veno.
There are no studies assessing the potential effect of epoetin alfa on male or female fertility. 
Ni študij, s katerimi bi ocenili možen vpliv epoetina alfa na plodnost pri moških ali ženskah.
The dose of Binocrit you receive is based on your body weight in kilograms. 
Odmerek zdravila Binocrit, ki ga boste prejeli, je odvisen od vaše telesne mase v kilogramih.
Do not administer Binocrit by intravenous infusion or in conjunction with other medicinal product solutions (please refer to section 6.6 for further information). 
Zdravila Binocrit ne dajajte v obliki intravenske infuzije ali v povezavi z drugimi raztopinami zdravil (glejte poglavje 6.6 za dodatne informacije).
• Always use Binocrit exactly as instructed by your doctor or nurse. 
• Zdravilo Binocrit vedno uporabljajte natančno po navodilih svojega zdravnika ali medicinske sestre.
For patients on peritoneal dialysis Binocrit may be given twice a week. 
Bolniki na peritonealni dializi lahko dobivajo zdravilo Binocrit dvakrat na teden.
• Your doctor may initiate treatment with Binocrit if your haemoglobin is 10 g/dL or less. 
• Vaš zdravnik lahko uvede zdravljenje z zdravilom Binocrit, ko je vaš hemoglobin 10 g/dl ali manj.
Following subcutaneous injection, serum levels of epoetin alfa reach a peak between 12 and 18 hours post-dose. 
Po subkutanem injiciranju dosežejo ravni epoetina alfa v serumu vrhunec med 12 in 18 urami po odmerku.
• You will usually continue Binocrit treatment for one month after the end of chemotherapy. 
• Običajno boste zdravilo Binocrit dobivali še en mesec po končanem zdravljenju s kemoterapijo.
Inject the Binocrit solution as you have been shown by your doctor. 
Injicirajte raztopino zdravila Binocrit, kot vam je pokazal zdravnik.
• Only use Binocrit if it has been stored correctly - see section 5, How to store Binocrit. 
• Uporabljajte le pravilno shranjeno zdravilo Binocrit - glejte poglavje 5, Shranjevanje zdravila Binocrit.
Your doctor has carried out blood tests and decided you need Binocrit. 
Vaš zdravnik je opravil krvne preiskave in odločil, da potrebujete zdravilo Binocrit.
This risk may be higher if you have other risk factors for developing blood clots (for example, if you have had a blood clot in the past or are overweight, have diabetes, have heart disease or you are off your feet for a long time because of surgery or illness). 
če imate druge dejavnike tveganja za nastanek krvnih strdkov (na primer, če ste v preteklosti imeli krvni strdek, če ste pretežki, imate sladkorno bolezen, bolezen srca ali dalj časa ne morete vstati zaradi kirurškega posega ali bolezni).
If you are a cancer patient, be aware that use of Binocrit may be associated with shorter survival and a higher death rate in head and neck, and metastatic breast cancer patients who are receiving chemotherapy. 
Če ste bolnik z rakom, morate vedeti, da je uporaba zdravila Binocrit lahko povezana s krajšim preživetjem in večjimi stopnjami smrtnosti pri bolnikih z rakom v glavi in vratu ter metastatskim rakom dojke, ki prejemajo zdravljenje s kemoterapijo.
Your doctor will help you to decide if Binocrit is suitable for you. 
Vaš zdravnik vam bo pomagal pri odločitvi, ali je zdravilo Binocrit za vas primerno.
Binocrit is provided with or without a needle safety guard and you will be shown how to use this by your doctor or nurse. 
Zdravilo Binocrit je opremljeno z zaščito za iglo ali pa je brez nje, vaš zdravnik ali medicinska sestra pa vam bosta pokazala, kako to uporabljati.
• The usual starting dose of Binocrit for adults and children is 50 International Units (IU) per kilogram (/kg) of body weight given three times a week. 
• Običajni začetni odmerek zdravila Binocrit za odrasle in otroke je 50 mednarodnih enot (i.e.) na kilogram (/kg) telesne mase, trikrat na teden.
Binocrit is given alone and not mixed with other liquids for injection. 
Zdravilo Binocrit se daje samo in se ne meša z drugimi tekočinami za injiciranje.
In those situations in which the physician determines that a patient or caregiver can safely and effectively administer Binocrit subcutaneously themselves, instruction as to the proper dosage and administration should be provided. 
Če zdravnik oceni, da lahko bolnik ali negovalec zdravilo Binocrit varno in učinkovito subkutano injicira sam, mu je treba dati navodila za pravilno odmerjanje in dajanje.
Binocrit should be administered after the completion of the blood donation procedure. 
Zdravilo Binocrit je treba uporabiti po tem, ko je postopek darovanja krvi končan.
During the maintenance phase, Binocrit can be administered either 3 times per week, and in the case of subcutaneous administration, once weekly or once every 2 weeks. 
Med vzdrževalno fazo se lahko zdravilo Binocrit daje bodisi 3-krat na teden ali v primeru subkutanega dajanja enkrat na teden ali enkrat na dva tedna.
• if you have been diagnosed with Pure Red Cell Aplasia (the bone marrow cannot produce enough red blood cells) after previous treatment with any product that stimulates red blood cell production (including Binocrit). 
• če so vam postavili diagnozo aplazija rdečih krvnih celic (kostni mozeg ne more tvoriti dovolj rdečih krvnih celic) po predhodnem zdravljenju s katerim koli zdravilom, ki spodbuja nastajanje rdečih krvnih celic (vključno z zdravilom Binocrit).
When this access (via a vein or tube) is not readily available, your doctor may decide that Binocrit should be injected under the skin (subcutaneously). 
Kadar takšen dostop (v veno ali cevko) ni takoj na razpolago, se vaš zdravnik lahko odloči, da je treba zdravilo Binocrit injicirati pod kožo (subkutano).
• If you do not respond adequately to Binocrit, your doctor will check your dose and will inform you if you need to change doses of Binocrit. 
• Če se na zdravljenje z zdravilom Binocrit ne odzivate ustrezno, bo zdravnik preveril vaš odmerek in vas obvestil, če morate spremeniti odmerke zdravila Binocrit.
Other medicines and Binocrit 
Druga zdravila in zdravilo Binocrit
• If you are having dialysis treatment when you begin treatment with Binocrit, your dialysis regime may need to be adjusted. 
• Če se zdravite z dializo, ko se začenjate zdraviti z zdravilom Binocrit, bo morda treba prilagoditi vaš režim dialize.
Binocrit can reduce the need for a blood transfusion. 
Binocrit lahko zmanjša potrebo po transfuziji krvi.
- Patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin should not receive Binocrit or any other erythropoietin (see section 4.4). 
- Bolniki, pri katerih se po zdravljenju s katerim koli eritropoetinom razvije aplazija rdečih krvnih celic (PRCA - pure red cell aplasia), ne smejo dobivati zdravila Binocrit ali katerega koli drugega eritropoetina (glejte poglavje 4.4).
• Binocrit is given by injection into a vein immediately after you have donated blood for 3 weeks before your surgery. 
• Zdravilo Binocrit se injicira v veno takoj po tem, ko darujete kri, 3 tedne pred kirurškim posegom.
Tell your doctor or nurse immediately if you are aware of any of these effects, or if you notice any other effects while you are receiving treatment with Binocrit. 
Zdravniku ali medicinski sestri takoj povejte, če ugotovite katerega koli od teh neželenih učinkov ali če med zdravljenjem z zdravilom Binocrit opazite druge neželene učinke.
Later, your doctor may suggest that you or your caregiver learn how to inject Binocrit under the skin 
Kasneje lahko zdravnik predlaga, da se vi ali vaš skrbnik naučite, kako si injicirati zdravilo Binocrit pod kožo (subkutano).
If you are a patient with chronic renal failure, and particularly if you do not respond properly to Binocrit, your doctor will check your dose of Binocrit because repeatedly increasing your dose of Binocrit if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death. 
Če ste bolnik s kronično ledvično odpovedjo, še zlasti, če se na zdravilo Binocrit ne odzivate ustrezno, bo zdravnik preveril vaš odmerek zdravila Binocrit, saj lahko stalno zviševanje vašega odmerka zdravila Binocrit, če se na zdravljenje ne odzivate, poveča tveganje za težave s srcem ali ožiljem in tudi tveganje za srčni infarkt, možgansko kap in smrt.
• in children on haemodialysis 
• pri otrocih na hemodializi
Because Binocrit stimulates the production of red blood cells, doctors can take more blood from these people. 
Ker zdravilo Binocrit spodbuja nastajanje rdečih krvnih celic, lahko zdravnik od teh ljudi vzame več krvi.
10, A-6250 Kundl, Austria 
10, A-6250 Kundl, Avstrija
You may still be able to use Binocrit, but discuss it with your doctor first: 
Morda boste lahko še vedno uporabljali zdravilo Binocrit, vendar se najprej posvetujte s svojim zdravnikom:
Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. 
Zdravilo Binocrit je indicirano pri odraslih v preddonorskem programu za povečanje količine pridobljene avtologne krvi.
While on Binocrit, some people need medicines to reduce the risk of blood clots. 
Med uporabo zdravila Binocrit morajo nekatere osebe jemati zdravila za zmanjšanje tveganja za nastanek krvnih strdkov.
• If you are on a more extended dosing interval (greater than once weekly) of Binocrit, you may not maintain adequate haemoglobin levels and you may require an increase in Binocrit dose or frequency of administration. 
• Če uporabljate daljši interval odmerjanja zdravila Binocrit (daljši kot enkrat tedensko), morda ne bo mogoče vzdrževati ustrezne ravni hemoglobina in bo treba odmerek ali pogostnost odmerjanja zdravila Binocrit povečati.
• Binocrit is given by injection under the skin each week for three weeks before surgery and on the day of surgery. 
• Zdravilo Binocrit se injicira pod kožo vsak teden tri tedne pred kirurškim posegom in na dan kirurškega posega.
• in adults on haemodialysis or peritoneal dialysis 
• pri odraslih bolnikih na hemodializi ali peritonealni dializi
If signs and symptoms suggestive of these reactions appear, Binocrit should be withdrawn immediately and an alternative treatment considered. 
Če se pojavijo znaki in simptomi, ki kažejo na te reakcije, je treba zdravljenje z zdravilom Binocrit takoj prekiniti in razmisliti o drugi vrsti zdravljenja.
Caution should be exercised with escalation of Binocrit doses in patients with chronic renal failure since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events. 
Previdnost je potrebna pri stopnjevanju odmerkov zdravila Binocrit pri bolnikih s kronično ledvično odpovedjo, saj so morda višji kumulativni odmerki epoetina povezani s povečanim tveganjem za umrljivost, resne kardiovaskularne in cerebrovaskularne dogodke.
Binocrit and other products that stimulate red cell production may increase the risk of developing blood clots in all patients. 
Zdravilo Binocrit in druga zdravila, ki spodbujajo nastajanje rdečih krvnih celic, lahko povečajo tveganje za nastanek krvnih strdkov pri vseh bolnikih.
Rare side effects These may affect up to 1 in 1,000 people. 
Redki neželeni učinki Pojavijo se lahko pri največ 1 od 1.000 bolnikov
If you visit a hospital, clinic or family doctor, tell them you are having Binocrit treatment. 
Če obiščete bolnišnico, kliniko ali izbranega zdravnika, povejte, da se zdravite z zdravilom
Mildly anaemic patients (haematocrit of 33 to 39%) requiring predeposit of ≥ 4 units of blood should be treated with Binocrit 600 IU/kg intravenously, 2 times per week for 3 weeks prior to surgery. 
Blago anemične bolnike (hematokrit 33 do 39 %), ki potrebujejo ≥ 4 enote deponirane krvi, je treba zdraviti z zdravilom Binocrit 600 i.e./kg, intravensko, 2-krat na teden, 3 tedne pred kirurškim posegom.
Treatment with Binocrit has to be initiated under the supervision of physicians experienced in the management of patients with the above indications. 
4.2 Odmerjanje in način uporabe Zdravljenje z zdravilom Binocrit je treba začeti pod nadzorom zdravnika, ki ima izkušnje z obravnavo bolnikov z zgoraj navedenimi indikacijami.
If you forget to use Binocrit 
Če ste pozabili uporabiti zdravilo Binocrit
If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Binocrit, treatment with Binocrit must not be restarted in this patient at any time. 
Če je pri bolniku zaradi uporabe zdravila Binocrit prišlo do hude kožne reakcije, kot sta SJS ali TEN, zdravljenja z zdravilom Binocrit ni dovoljeno ponovno začeti.
• Your doctor will order blood tests, and may adjust the dose, depending on how your anaemia responds to Binocrit treatment. 
• Vaš zdravnik bo naročil krvne preiskave in po potrebi prilagodil odmerek, odvisno od odziva vaše anemije na zdravljenje z zdravilom Binocrit.
In patients with a poor haemoglobin response to Binocrit, alternative explanations for the poor response should be considered (see section 4.4 and 5.1). 
Pri bolnikih s slabim odzivom hemoglobina na zdravilo Binocrit je treba iskati druge razlage za slab odziv (glejte poglavji 4.4 in 5.1).
Your Binocrit dose and frequency of administration may be further adjusted to maintain your response to treatment. 
Po potrebi vam lahko odmerek zdravila Binocrit in pogostnost uporabe nadalje prilagaja, da se ohrani vaš odziv na zdravljenje.
Patients should be monitored closely to ensure that the lowest approved effective dose of Binocrit is used to provide adequate control of anaemia and of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dL (7.5 mmol/L). 
Bolnike je treba skrbno spremljati, da se zagotovi uporaba najmanjšega odobrenega učinkovitega odmerka zdravila Binocrit za doseganje ustreznega nadzora anemije in simptomov anemije ob hkratnem ohranjanju koncentracije hemoglobina pod ali pri 12 g/dl (7,5 mmol/l).
1 Common in dialysis 2 Includes arterial and venous, fatal and non fatal events, such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, arterial thrombosis (including myocardial infarction), cerebrovascular accidents (including cerebral infarction and cerebral haemorrhage) transient ischaemic attacks, and shunt thrombosis (including dialysis equipment) and thrombosis within arteriovenous shunt aneurisms 3 Addressed in the subsection below and/or in section 4.4 
1 Pogosto pri dializi 2 Vključuje arterijske in venske dogodke, s smrtnim izidom in brez njega, kot so globoka venska tromboza, pljučna embolija, tromboza mrežnice, arterijska tromboza (vključno z miokardnim infarktom), cerebrovaskularne dogodke (vključno s cerebralnim infarktom in cerebralno krvavitvijo), prehodne ishemične napade in trombozo šanta (vključno z dializno opremo) in trombozo v arteriovenskih anevrizmah šanta 3 Opisano v spodnjem podpoglavju in/ali v poglavju 4.4
These may affect more than 1 in 10 people. 
Pojavijo se lahko pri več kot 1 od 10 bolnikov
Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dL or 6.2 to 8.1 mmol/L) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1,800 mL). 
Uporabo je treba omejiti na bolnike z zmerno anemijo (npr. razpon koncentracije hemoglobina od 10 do 13 g/dl ali od 6,2 do 8,1 mmol/l), ki jim program avtolognega darovanja krvi ni na voljo in pri katerih se pričakuje zmerna izguba krvi (od 900 do
After single doses (20,000 to 160,000 IU subcutaneously) of epoetin alfa, a dose-dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin. 
Po enkratnem odmerjanju (20.000 do 160.000 i.e. subkutano) epoetina alfa so opazili od odmerka odvisen odziv preučevanih farmakodinamičnih markerjev, vključno z retikulociti, RKC in hemoglobinom.
Iron supplements and other blood stimulants may increase the effectiveness of Binocrit. 
Dodatki železa in druga sredstva za spodbujanje tvorbe krvi lahko povečajo učinkovitost zdravila
You may still be able to use Binocrit, but discuss it with your doctor first. 
Morda boste kljub temu lahko uporabljali zdravilo Binocrit, vendar se najprej posvetujte s svojm zdravnikom.
Caution should be exercised with escalation of Binocrit doses in patients with chronic renal failure. 
Previdnost je potrebna pri stopnjevanju odmerkov zdravila Binocrit pri bolnikih s kronično ledvično odpovedjo.
These include venous and arterial thromboses and embolism (including some with fatal outcomes), such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, and myocardial infarction. 
Ti vključujejo venske in arterijske tromboze in embolizem (vključno z nekaj smrtnimi izidi), kot so globoka venska tromboza, pljučna embolija, tromboza mrežnice in miokardni infarkt.
Binocrit is a biosimilar medicinal product. 
Zdravilo Binocrit je podobno biološko zdravilo.
Binocrit may be given by injection: 
Zdravilo Binocrit se lahko daje z injiciranjem:
The recommended dose is Binocrit 600 IU/kg, administered subcutaneously weekly for three weeks (days -21, -14 and -7) prior to surgery and on the day of surgery (day 0). 
Priporočeni odmerek zdravila Binocrit je 600 i.e./kg, ki se daje subkutano tedensko v obdobju treh tednov (na 21., 14. in 7. dan) pred kirurškim posegom in na dan kirurškega posega (dan 0).
Binocrit is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does. 
Zdravilo Binocrit je eno od zdravil iz skupine, ki spodbuja nastajanje rdečih krvnih celic na enak način kot humana beljakovina eritropoetin.
Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range between 10 to 13 g/dL [6.2 to 8.1 mmol/L], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). 
Zdravilo Binocrit smemo uporabiti samo pri bolnikih z zmerno anemijo (razpon koncentracije hemoglobina [Hb] od 10 do 13 g/dl [6,2 do 8,1 mmol/l] brez pomanjkanja železa), če postopki za ohranjanje krvi niso na voljo ali ne zadostujejo, kadar je za večji elektivni kirurški poseg potrebna velika količina krvi (4 ali več enot krvi za ženske ali 5 ali več enot za moške).
The mean volume of distribution was 49.3 mL/kg after intravenous doses of 50 and 100 IU/kg in healthy subjects. 
Povprečni volumen porazdelitve je bil pri zdravih osebah 49,3 ml/kg po intravenskih odmerkih 50 in 100 i.e./kg.
If you are taking a medicine called cyclosporin (used e.g. after kidney transplants), your doctor may order blood tests to check the level of cyclosporin while you are taking Binocrit. 
Če med zdravljenjem z zdravilom Binocrit jemljete zdravilo, imenovano ciklosporin (uporablja se npr. po presaditvi ledvic), lahko zdravnik naroči preiskave krvi, da preveri raven ciklosporina,
If you are given a product in this group other than Binocrit during your treatment, speak to your doctor or pharmacist before using it. 
Če med zdravljenjem dobite drugo zdravilo iz te skupine, kot zdravilo Binocrit, se pred uporabo posvetujte s svojim zdravnikom ali farmacevtom.
When treatment starts, Binocrit is usually injected by a medical professional or a nurse. 
Na začetku zdravljenja vam bo zdravilo Binocrit običajno injiciral zdravnišk ali medicinsko osebje.
No studies on the effects on the ability to drive and use machines have been performed. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Študij o vplivu na sposobnost vožnje in upravljanja s stroji niso izvedli.
• Binocrit is given by injection under the skin. 
• Zdravilo Binocrit se daje v obliki injekcije pod kožo.
This section contains information on how to give yourself an injection of Binocrit. 
To poglavje vsebuje navodila za to, kako morate sami sebi dajati injekcije zdravila Binocrit.
Where intravenous access is not readily available (patients not yet undergoing dialysis and peritoneal dialysis patients) Binocrit may be administered as a subcutaneous injection. 
Kjer intravenski dostop ni takoj na razpolago (bolniki, ki se še ne zdravijo z dializo, in bolniki na peritonealni dializi), se zdravilo Binocrit lahko daje v obliki subkutane injekcije.
Binocrit is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. 
Zdravilo Binocrit je indicirano za zdravljenje odraslih, pri katerih s kemoterapijo zdravimo solidne tumorje, maligni limfom ali multipli mielom, in pri tveganju za transfuzijo, ki ga ocenimo glede na bolnikovo splošno zdravstveno stanje (npr. kardiovaskularni status, prisotnost anemije že na začetku zdravljenja s kemoterapijo) za zdravljenje anemije in zmanjšanje potrebe po transfuziji.
• Before use, leave the Binocrit syringe to stand until it reaches room temperature. 
• Pred uporabo počakajte, da zdravilo Binocrit doseže sobno temperaturo.
The recommended starting dose is Binocrit 450 IU/kg (maximum total dose is 40,000 IU) administered subcutaneously once every week, with not less than 5 days between doses. 
Priporočeni začetni odmerek zdravila Binocrit je 450 i.e./kg (največji skupni odmerek je 40.000 i.e.), ki se daje subkutano enkrat na teden, pri čemer med odmerkoma ne sme miniti manj kot 5 dni.